MicroRNA, mRNA, and Proteomics Biomarkers and Therapeutic Targets for Improving Lung Cancer Treatment Outcomes

• Published in: Cancers 2023-04, Vol.15 (8), p.2294
• Main Authors: Ye, Qing, Raese, Rebecca, Luo, Dajie, Cao, Shu, Wan, Ying-Wooi, Qian, Yong, Guo, Nancy Lan
• Format: Article
• Language: English
• Subjects: AKT protein; Anthracycline; Artificial intelligence; Bioinformatics; Biological markers; Biomarkers; Cancer; Cancer therapies; Care and treatment; Cell cycle; CRISPR; Daunorubicin; Disease; Drug development; Drug therapy; Ethylenediaminetetraacetic acid; Gene expression; Genes; Genetic aspects; Genomes; Health aspects; Lung cancer; Medical prognosis; Medical research; Medicine, Experimental; Messenger RNA; Metastases; Metastasis; MicroRNA; MicroRNAs; miRNA; mRNA; Pathology; Patient outcomes; Patients; Protein kinase inhibitors; Proteins; Proteomics; Radiation therapy; Respiratory agents; RNA-mediated interference; Survival; Therapeutic targets; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15082294

The majority of lung cancer patients are diagnosed with metastatic disease. This study identified a set of 73 microRNAs (miRNAs) that classified lung cancer tumors from normal lung tissues with an overall accuracy of 96.3% in the training patient cohort ( = 109) and 91.7% in unsupervised classification and 92.3% in supervised classification in the validation set ( = 375). Based on association with patient survival ( = 1016), 10 miRNAs were identified as potential tumor suppressors (hsa-miR-144, hsa-miR-195, hsa-miR-223, hsa-miR-30a, hsa-miR-30b, hsa-miR-30d, hsa-miR-335, hsa-miR-363, hsa-miR-451, and hsa-miR-99a), and 4 were identified as potential oncogenes (hsa-miR-21, hsa-miR-31, hsa-miR-411, and hsa-miR-494) in lung cancer. Experimentally confirmed target genes were identified for the 73 diagnostic miRNAs, from which proliferation genes were selected from CRISPR-Cas9/RNA interference (RNAi) screening assays. Pansensitive and panresistant genes to 21 NCCN-recommended drugs with concordant mRNA and protein expression were identified. DGKE and WDR47 were found with significant associations with responses to both systemic therapies and radiotherapy in lung cancer. Based on our identified miRNA-regulated molecular machinery, an inhibitor of PDK1/Akt BX-912, an anthracycline antibiotic daunorubicin, and a multi-targeted protein kinase inhibitor midostaurin were discovered as potential repositioning drugs for treating lung cancer. These findings have implications for improving lung cancer diagnosis, optimizing treatment selection, and discovering new drug options for better patient outcomes.